Join the club for FREE to access the whole archive and other member benefits.

Gregory Bailey

CEO at Juvenescence and chairman of Portage Biotech

Dr. Gregory Bailey is chairman of Portage Biotech, Inc. a publicly traded drug development company and was previously managing partner of Palantir Group, Inc., a merchant bank specialising in biotech and intellectual property. He has over 15 years of experience in investment banking and has founded several companies. 

Along with comprehensive experience in healthcare, finance and medicine, Greg brings an extensive involvement in corporate governance. He has co-founded and served on multiple public and private company boards of directors, such as Palantir Group, Inc., Ascent Healthcare Solutions, VirnetX Inc. (VHC:AMEX), Portage Biotech Inc. (PTGEF: OTCBB), DuraMedic Inc., and MediqVentures Ltd.

Visit website:


See also: Company Juvenescence - Developing therapies against different aging related diseases.

Details last updated 21-Nov-2019

Gregory Bailey is also referenced in the following:

Investing in the Future of Longevity – the Ketone Chapter


Juvenescence webinar about the latest research and developments on future of longevity investment

Longevity Investors Conference 2023

27-Sep-2023 to 29-Sep-2023

Conference gathering longevity experts and investors at one place hosted by Marc P. Bernegger, Dr. Tobias Reichmuth and Daniel Koetser

Longevity Leaders World Congress 2021

04-May-2021 to 07-May-2021

The virtual event for leaders in longevity science, technology, business and finance organized by Longevity Leaders (LSX).

Longevity Leaders World Congress 2022

26-Feb-2022 to 27-Feb-2022

Event for leaders in longevity science, technology, business and finance organized by Longevity Leaders (LSX)

Gregory Bailey News

Labiotech gathers feedback from European biotechs on Unity failure

Labiotech - 28-Aug-2020

General feeling that failures are bound to happen - but that their approaches can succeed


Juvenescence appoints a new CEO for its Epigenetic Division and Souvien Bio Ltd

Juvenescence - 11-Jun-2020

Goal is to develop drugs that target epigenetic mechanisms associated with neurodegeneration


Today's 50 year-olds may live another 100 years

Forbes - 26-Aug-2019

Good summary of some major investments in life extension companies


FoxBio is developing small molecule drugs to target ageing diseases

Business Wire - 12-Jul-2018

Antoxerene partners with Juvenescence to discover drugs that clear senescent cells


UK biotech company focused on developing anti-ageing therapies

PMLiVE - 12-Jun-2018

LyGenesis seeks to use a patient’s own lymph nodes as bioreactors to grow functioning ectopic organs


British billionaire gambles on an anti-aging upstart

Endpoints News - 26-Jul-2017

We are at an inflection point for the treatment of aging. We can generate molecules with specifi...